Twist Bioscience Corporation (NASDAQ: TWST), a company that provides synthetic DNA using its silicon platform, has announced a strategic collaboration with LakePharma Inc, a US-based biologics company.

It was reported on Friday that the collaboration is aimed at offering antibody discovery and development solutions to pharmaceutical and biotechnology customers.

According to the terms of the contract, LakePharma will have the ability to offer Twist's proprietary antibody discovery and optimisation platforms to its existing and future biopharmaceutical customers as part of its service offerings. One such platform generated is for discovery of novel therapeutic antibodies against a major class of protein drug targets known as GPCRs, which traditionally have been difficult for biologics drug development. GPCRs have been heavily investigated due to their involvement in multiple disease classes, including inflammation, cancer, metabolism, respiratory, and pain.

In return, Twist customers will have access to LakePharma's integrated discovery and development services.